Zuora's optimistic future outlook isn't fully reflected in its current share price. However, its high beta suggests potential future buying opportunities if the price sinks lower.
Zuora's loss-making status and negative free cash flow make it a risky investment. However, its net cash position provides some financial cushion. Its growth rate is deemed slow, and its balance sheet and future earnings will determine its ability to maintain a healthy balance sheet.
Zuora's share price shows recent improvement, possibly indicating a positive business shift. Yet, its long-term performance, a roughly 9% annual loss over five years, is more significant. Three warning signs with Zuora should be considered in investment decisions.
$Zuora (ZUO.US)$a leading cloud-based subscription management platform, today announced a multi-tiered agreement with Microsoft to integrate several Microsoft products with Zuora®.Today’s companies are looking for a new level of business agility to deploy new business models, launch product lines, and expand internationally. At the same time, they need their applications and platforms to help them scale to IPO and beyond. These new integrated solutions will deliver finance teams more agility, power enhanced subscription analytics, and make it easier than ever to deploy and adopt technology from two enterprise leaders.
$Zuora (ZUO.US)$, a leading cloud-based subscription management platform, today announced a multi-tiered agreement with Microsoft to integrate several Microsoft products with Zuora®. Today’s companies are looking for a new level of business agility to deploy new business models, launch product lines, and expand internationally. At the same time, they need their applications and platforms to help them scale to IPO and beyond. These new integrated solutions will deliver finance teams more agility, power enhanced subscription analytics, and make it easier than ever to deploy and adopt technology from two enterprise leaders.
Zuora Stock Forum
Major Tech Deal: Silver Lake Acquires Zuora at Premium - Strategic Growth Plans Unveiled
📊⚡️📊
up ⬆️⬆️⬆️⬆️⬆️
Today’s companies are looking for a new level of business agility to deploy new business models, launch product lines, and expand internationally. At the same time, they need their applications and platforms to help them scale to IPO and beyond. These new integrated solutions will deliver finance teams more agility, power enhanced subscription analytics, and make it easier than ever to deploy and adopt technology from two enterprise leaders.
$VIZIO(Delisted) (VZIO.US)$
$Fulgent Genetics (FLGT.US)$
$Cara Therapeutics (CARA.US)$
$KnowBe4 (KNBE.US)$
$Coursera (COUR.US)$
$Intellia Therapeutics (NTLA.US)$
$Natera (NTRA.US)$
$DraftKings (DKNG.US)$
$Natural Alternatives International (NAII.US)$
$Revolve Group (RVLV.US)$
$A10 Networks (ATEN.US)$
$Zuora (ZUO.US)$
Insider Buying
$Spero Therapeutics (SPRO.US)$
$Lumos Pharma (Delisted) (LUMO.US)$
$Oscar Health (OSCR.US)$
$Phibro Animal Health (PAHC.US)$
No comment yet